Inhibition of TNF-α gene expression and bioactivity by site-specific transcription factor-binding oligonucleotides

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 284, Issue 2 28-2, 2003, Pages

  Ye, Jianping ^a   Wang, Liying ^b   Zhang, Xiaoying ^a   Tantishaiyakul, Vimon ^c   Rojanasakul, Yon ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Tumor necrosis factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; TRANSCRIPTION REGULATION;

EID: 0037309547     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00134.2002     Document Type: Article

References (45)

1. Baeuerle PA. The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochim Biophys Acta 1072: 63-80, 1991.
2. Baeuerle PA and Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 12: 141-179, 1994.
3. Bennett FC, Chiang MY, Chan HC, Shoemaker JEE, and Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41: 1023-1033, 1992.
4. Beutler B. Application of transcriptional and posttranscriptional reporter constructs to the analysis of tumor necrosis factor gene regulation. Am J Med Sci 303: 129-133, 1992.
5. Bielinska A, Shivdasani RA, Zhang LQ, and Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 250: 997-1000, 1990.
6. Chang SW. Endotoxin-induced pulmonary leukostasis in the rat: role of platelet-activating factor and tumor necrosis factor. J Lab Clin Med 123: 65-72, 1994.
7. Chen FE, Huang DB, Chen YQ, and Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature 391: 410-413, 1998.
8. Collart MA, Baeuerle PA, and Vassal P. Regulation of tumor necrosis factor-α transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 10: 1498-1506, 1990.
9. Collins T, Read MA, Neish AS, Whiteley MZ, Thanos D, and Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 9: 899-909, 1995.
10. Dokka S, Malanga CJ, Shi X, Chen F, Castranova V, and Rojanasakul Y. Inhibition of endotoxin-induced lung inflammation by interleukin-10 gene transfer in mice. Am J Physiol Lung Cell Mol Physiol 279: L872-L877, 2000.
11. Dokka S, Toledo D, Castranova V, Shi X, and Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by cationic liposomes. Pharm Res 17: 521-525, 2000.
12. Drouet C, Shakhov AN, and Jongeneel CV. Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-α promoter in primary macrophages. J Immunol 147: 1694-1700, 1991.
13. Economou JS, Rhoades K, Essner R, McBride WH, Gasson JC, and Morton DL. Genetic analysis of the human tumor necrosis factor-α/cachectin promoter region in a macrophage cell line. J Exp Med 170: 321-326, 1989.
14. Foxwell B, Browne K, Bondeson J, Clarke C, de Martin R, Brennan F, and Feldmann M. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor-α production in rheumatoid arthritis is NF-κB dependent. Proc Natl Acad Sci USA 95: 8211-8215, 1998.
15. Gilar M, Belenky A, Smisek DL, Bourque A, and Cohen AS. Kinetics of phosphorothioate oligonucleotide metabolism in biological fluids. Nucleic Acids Res 25: 3615-3620, 1997.
16. Hensel G, Meichle A, Pfizenmaier K, and Kronke M. PMA-responsive 5′ flanking sequences of the human TNF gene. Lymphokine Res 8: 347-351, 1989.
17. Juliano RL and Akhtar S. Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res Dev 2: 165-176, 1992.
18. Kolls J, Peppel K, Silva M, and Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 91: 215-219, 1994.
19. Kramer B, Meichle A, Hensel G, Charnay P, and Kronke M. Characterization of a Krox-24/Erg-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1219: 413-421, 1994.
20. Kramer B, Wiegmann K, and Kronke M. Regulation of the human TNF promoter by the transcription factor Ets. J Biol Chem 270: 6577-6583, 1995.
21. Kuprash DV, Udalova IA, Turetskaya RL, Kwiatkowski D, Rice NR, and Nedospasov SA. Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J Immunol 162: 4045-4052, 1999.
22. Li S and Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 4: 891-900, 1997.
23. Lukacs NW and Ward PA. Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury. Adv Immunol 62: 257-304, 1996.
24. Mann MJ and Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 106: 1071-1075, 2000.
25. McCaffrey PG, Goldfeld AE, and Rao A. The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-α gene transcription. J Biol Chem 269: 30445-30450, 1994.
26. McLachlan G, Davidson DJ, Stevenson BJ, Dickinson P, Davidson-Smith H, Dorin JR, and Porteous DJ. Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther 2: 614-622, 1995.
27. McLachlan G, Ho LP, Davidson-Smith H, Samways J, Davidson H, Stevenson BJ, Carothers AD, Alton EW, Middleton PG, Smith SN, Kallmeyer G, Michaelis U, Seeber S, Naujoks K, Greening AP, Innes JA, Dorin JR, and Porteous DJ. Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Ther 3: 1113-1123, 1996.
28. Meyer KB, Thompson MM, Levy MY, Barron LG, and Szoka FCJ. Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics. Gene Ther 2: 450-460, 1995.
29. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, and Freier SM. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267: 19954-19962, 1992.
30. Pope RM, Leutz A, and Ness SA. C/EBP β regulation of the tumor necrosis factor-α gene. J Clin Invest 94: 1449-1455, 1994.
31. Rhoades KL, Golub SH, and Economou JS. The regulation of the human tumor necrosis factor-α promoter region in macrophage, T cell, and B cell lines. J Biol Chem 267: 22102-22107, 1992.
32. Rojanasakul Y. Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv Drug Delivery Res 18: 115-131, 1996.
33. Rojanasakul Y, Weissman DN, Shi X, Castranova V, Ma JKH, and Liang W. Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages. J Biol Chem 272: 3910-3914, 1997.
34. Sander C. Genomic medicine and the future of health care. Science 287: 1977-1978, 2000.
35. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, and Jongeneel CV. κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor-α gene in primary macrophages. J Exp Med 171: 35-47, 1990.
36. Tracey KJ and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45: 491-503, 1994.
37. Traenkner BM, Wilk S, and Baeuerle PA. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκB-α that is still bound to NF-κB. EMBO J 13: 5433-5441, 1994.
38. Tsai EY, Jain J, Pesavento PA, Rao A, and Goldfeld AE. Tumor necrosis factor-α gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 16: 459-467, 1996.
39. Tsai EY, Yie J, Thanos D, and Goldfeld AE. Cell type-specific regulation of human tumor necrosis factor-α gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol 16: 5232-5244, 1996.
40. Wagner RW, Matteucci MD, Lewis JL, Gutierrez AJ, Moulds C, and Froehler BC. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260: 1510-1513, 1993.
41. Warren HS, Danner RL, and Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 326: 1151-1153, 1992.
42. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, and Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA 85: 1028-1032, 1988.
43. Yao J, Mackman N, Edgington TS, and Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. Regulation by Erg-1, c-Jun, and NF-κB transcription factors. J Biol Chem 272: 17795-17801, 1997.
44. Ye J, Aeidler P, Young S, Martinez A, Robinson VA, Jones W, Baron P, Shi X, and Castranova V. Activation of mitogen-activated protein kinase p38 and extracellular signal-regulated kinase is involved in glass fiber-induced tumor necrosis factor-α production in macrophages. J Biol Chem 276: 5360-5367, 2001.
45. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, and Teng NN. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibodies against endotoxin. N Engl J Med 324: 429-436, 1991.